Use of atractylone, atractylone-containing plant and atractylone extract in preparing influenza virus resisting medicine

Abstract

The present invention discloses the effective cold virus resisting effective component, atractylone, and features that atractylone and Chinese medicine or extract containing atractylone have effect of resisting influenza A and B virus. Extracorporeal experiments show that atractylone in concentration of 1 mg/ml has the effect of killing influenza A virus H3N2 subtype, high pathogenic bird flu virus H5N1 subtype and influenza B virus strain. All the said atractylone, Chinese medicine or extract containing atractylone may be used as the medicine for human body and animal to prevent and treat influenza and bird flu, and may be prepared into tablet, capsule, granule, oral liquid, injection, inhalant and spray.

Description

technical field [0001] The invention relates to application of atractylone, atractylone-containing plant and atractylone extract in preparing anti-influenza virus medicine. Background technique [0002] Influenza (Influenza), referred to as influenza, is an acute respiratory infectious disease caused by influenza virus. It is mainly spread by air droplets. There are three types of influenza virus, A, B, and C. Because type A is prone to mutation, the influenza epidemic caused by it is the most extensive and serious. Type B often causes outbreaks, and Type C often causes sporadic cases in children. Once influenza is prevalent, it spreads quickly and affects a wide range of people. It has a great impact on people's health and labor productivity, and it poses a great threat to the elderly, infirm and infants, and often dies due to complications. At present, influenza is a key surveillance disease in China, and it is listed as a Class C infectious disease in my country's "Law...

AI Technical Summary

Problems solved by technology

The currently available anti-influenza drugs are only amantadine and methylamantadine, which are only effective against influenza A, and are likely to cause adverse reactions in the nervous system and digestive system, and long-term use is prone to drug resistance

Zanamivir (Zanamivir) and Oseltamivir (Oseltamivir) are being developed into clinical research, both of which are neuraminidase inhibitors. Although they are effective against influenza A and type B, their curative effect is poor. It is ineffective for infection and has side effects such as nausea and vomiting. It has not been approved for the prevention of influenza

Images